Plasma concentration of Fas/Fas ligand and left ventricular function in response to metoprolol in conjunction with standard treatment

Clinical Science

Volumn 112, Issue 5-6, 2007, Pages 299-304

  Hou, Yuan Ping ^a   Wu, Jin Ling ^a   Fan, Qian ^a   Liu, Miao Bing ^a   Yin, Bao Ling ^a   Zhang, Lin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

blocker; Angiotensin converting enzyme (ACE) inhibitor; Apoptosis; Congestive heart failure; Fas; Left ventricular function

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAS LIGAND; LOSARTAN; METOPROLOL;

ADULT; AGED; APOPTOSIS; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; SINUS BRADYCARDIA; WALKING;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; DIGOXIN; DIURETICS; DRUG THERAPY, COMBINATION; EXERCISE TEST; FAS LIGAND PROTEIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VENTRICULAR FUNCTION, LEFT;

EID: 33847771358     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060213     Document Type: Article

References (31)

1. Kang, P. M. and Izumo, S. (2003) Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol. Med. 9, 177-182
2. Adamopoulos, S., Parissis, J. T., Georgiadis, M. et al. (2002) Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am. Heart J. 144, 359-364
3. Parissis, J. T., Adamopoulos, S., Karatzas, D., Paraskevaidis, J., Livanis, E. and Kremastinos, D. (2005) Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur. J. Cardiovasc. Prev. Rehabil. 12, 164-168
4. Nishigaki, K., Minatoguchi, S., Seishima, M. et al. (1997) Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J. Am. Coll. Cardiol. 29, 1214-1220
5. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T. and Nagata, S. (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6, 1567-1574
6. Yamaguchi, S., Yamaoka, M., Okuyama, M. et al. (1999) Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am. J. Cardiol. 83, 1500-1503
7. Wollen, K. C., Heineke, J., Westermann, J. et al. (2000) The cardiac Fas (APO-1/CD95) Receptor/Fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation 101, 1172-1178
8. Yue, T. L., Ma, X. L., Wang, X. et al. (1998) Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ. Res. 82, 166-174
9. Sabbah, H. N., Sharov, V. G., Gupta, R. C., Todor, A., Singh, V. and Goldstein, S. (2000) Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J. Am. Coll. Cardiol. 36, 1698-1705
10. Guyatt, G. H., Sullivan, M. J., Thompson, P. J. et al. (1985) The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can. Med. Assoc. J. 132, 919-923
11. Orlinick, J. R., Vaishnaw, A. K. and Elkon, K. B. (1999) Structure and function of Fas/Fas ligand. Int. Rev. Immunol. 18, 293-308
12. Takemura, G., Kato, S., Aoyama, T. et al. (2001) Characterization of ultrastructure and its relation with DNA fragmentation in Fas-induced apoptosis of cultured cardiac myocytes. J. Pathol. 193, 546-556
13. Landmesser, U. and Drexler, H. (2005) Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat. Clin. Pract. Cardiovasc. Med. 2, 628-638
14. Rossig, L., Haendeler, J., Mallat, Z. et al. (2000) Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J. Am. Coll. Cardiol. 36, 2081-2089
15. Adams, J. W. and Brown, J. H. (2001 ) G-proteins in growth and apoptosis: lessons from the heart. Oncogene 20, 1626-1634
16. Communal, C., Singh, K., Pimentel, D. R. and Colucci, W. S. (1998) Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 98, 1329-1334
17. Kobara, M., Tatsumi, T., Kambayashi, D. et al. (2003) Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J. Cardiovasc. Pharmacol. 41, 880-889
18. (1990) Studies of left ventricular dysfunction (SOLVD): rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am. J. Cardiol. 66, 315-322
19. Filippatos, G. and Uhal, B. D. (2003) Blockade of apoptosis by ACE inhibitors and angiotensin receptor antagonists. Curr. Pharm. Des. 9, 707-714
20. Holm, A. M., Andersen, C. B., Haunso, S. and Hansen, P. R. (2000) ACE-inhibition promotes apoptosis after balloon injury of rat carotid arteries. Cardiovasc. Res. 45, 777-782
21. Communal, C. and Colucci, W. S. (2005) The control of cardiomyocyte apoptosis via the β-adrenergic signaling pathways. Arch. Mal. Coeur Vaiss. 98, 236-241
22. Rich, M. W., McSherry, F., Williford, W. O. and Yusuf, S. (2001) Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J. Am. Coll. Cardiol. 38, 806-813
23. +-ATPase in human breast cancer cells. Mol. Pharmacol. 67, 929-936
24. Kurup, R. K. and Kurup, P. A. (2003) Hypothalamic digoxin, geomagnetic fields and human disease: a hypothesis. Med. Hypotheses 60, 237-242
25. Lopez-Lazaro, M., Pastor, N., Azrak, S. S., Ayuso, M. J., Austin, C. A. and Cortes, F. (2005) Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 68, 1642-1645
26. Ichinose, M., Yonemochi, H., Sato, T. and Saikawa, T. (2003) Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress. Am. J. Physiol Heart Circ. Physiol. 284, H2235-H2241
27. Eliseev, R. A., Vanwinkle, B., Rosier, R. N. and Gunter, T. E. (2004) Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFκB. J. Biol. Chem. 279, 46748-46754
28. Sharov, V. G., Todor, A. V. and Sabbah, H. N. (2005) Left ventricular histomorphometric findings in dogs with heart failure treated with the Acorn Cardiac Support Device. Heart Fail. Rev. 10, 141-147
29. Sabbah, H. N., Sharov, V. G., Gupta, R. C. et al. (2003) Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ. Res. 93, 1095-1101
30. Kukin, M. and Moskowitz, R. (1999) β-Blockers in congestive heart failure. Expert Opin. Invest. Drugs 8, 1795-1805
31. Goussev, A., Sharov, V. G., Shimoyama, H. et al. (1998) Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am. J. Physiol. 275, H626-H631